Top 50 Life Science VC (Venture Capital) Funds in May 2026

Portfolio highlights

• MixRift — MIXRIFT - game developers specialized in Mixed Reality
• unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
• Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Portfolio highlights

• NodThera — NodThera is a biotechnology company treating chronic diseases by targeting inflammation at its source.
• Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
• T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .

Portfolio highlights

• SciNeuro — Courage Drives Change - We follow the science to deliver therapeutic solutions for CNS diseases
• Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
• Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.

Portfolio highlights

• Tr1x — Tr1x develops cellular therapies intended for the treatment of autoimmune disorders.
• Proxima — Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes. It focuses on creating proximity-modulating therapeutics that direct protein interactions for potential use in conditions such as autoimmune disorders and cancer, expanding the range of targets that traditional drugs cannot easily reach.Proxima Bio combines structural biology, data generation, and machine learning to identify actionable protein-protein interfaces and support the discovery of new therapeutic modalities. The company works with pharmaceutical partners to apply its platform in research collaborations and advance drug discovery pipelines. Proxima Bio’s platform integrates multiple technologies to support the design and discovery of novel proximity-based treatment approaches.
• NILO Therapeutics — A neuronal circuit regulates the immune system. We're targeting it to treat autoimmune and inflammatory diseases.

Portfolio highlights

• Vizgen — Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The highthroughput and resolution and the low cost per cell achieved by the technology will enable a wide range of tissue-scale basic research and development and will be instrumental to efforts to discover and map cell types and states in a range of tissues and organisms.
• Octave — Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States.
• Elephas — Elephas is a live tumor imaging company developing novel cancer diagnostic solutions to predict treatment outcomes and accelerate drug development.

Portfolio highlights

• Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.
• Microtide Biotechnology — Microtide Biotechnology is an innovative company specializing in the field of in vivo cell therapy. The company is dedicated to advancing next-generation biomedical technologies that harness the body’s own cellular mechanisms for disease treatment, focusing on developing safe, effective, and precise therapeutic solutions to improve patient outcomesand redefine the future of regenerative medicine.
• Sparrow Pharmaceuticals — Sparrow Pharmaceuticals is an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess.

Portfolio highlights

• Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
• Ceryx Medical — Ceryx Medical Ltd are the revolutionary business behind a unique bioelectronic technology that could change the way diseases such as heart failure are treated.
• Enhanc3D Genomics — Enhanc3D Genomics is a spinout company from Babraham Institute.

Portfolio highlights

• Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
• NRG Therapeutics — energizing drug discovery in neurodegenerative diseases.
• Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.

Portfolio highlights

• Capacity Bio — Capacity Bio is a private, biotech company developing a first-in-class mitophagy therapeutic platform, along with the most advanced analytical toolkit to characterize mitochondria.
• Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.
• Avalanche Energy — Avalanche Energy operates as a fusion energy start-up.

Portfolio highlights

• Vercel — Vercel gives developers the frameworks, workflows, and infrastructure to build a faster, more personalized web.
• Iterative Health — Iterative Health is a healthcare technology and services company that focuses on accelerating clinical research to improve patient outcomes through innovative approaches. The company transforms gastrointestinal (GI) care by utilizing AI-driven clinical trials and diagnostics, significantly enhancing access to vital treatments.
• Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.

Portfolio highlights

• Halter — Halter creates GPS enabled, solar powered collars for cows. The collar hardware allows farmers to use simple tablet app software to remotely set geographic boundaries for cattle, virtual fences. Farmers use Halter's system to avoid physically herding cows, maximizing farmer time and productivity.
• evonetix — evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniqueswe are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.
• Fourth Power — Fourth Power makes renewable energy an on-demand energy source through utility-scale, thermal battery technology. With the ability to provide flexible-duration energy storage, we can start small and grow with the grid to save consumers money and ensure a clean energy future.

Portfolio highlights

• Farcast — Unlocking satellite internet capacity through user terminal innovation
• Deepcell — Deepcell uses AI to isolate and capture cells based on morphological features for multiple research and translational applications.
• Electroflow Technologies — Electroflow Technologies Inc.: Start-up working on direct Lithium extraction and refinement from low concentration brines using renewable electricity and minimal chemicals.

Portfolio highlights

• Allos — Allos replaces trial-and-error with causal AI to bring physical rigor to pharmaceutical manufacturing, reducing experiments and making decisions evidence-based and defensible.
• Neu Health — Neu Health enables clinicians, care givers and patients to tackle this growing challenge with cutting-edge digital technologies designed to make the latest care accessible for all, improving outcomes today and accelerating future breakthroughs.
• Pepgen — PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides,and they are advancing novel conjugate therapeutics to the clinic.

Portfolio highlights

• MFX — MFX is a platform designed to accelerate the development and manufacturing of cell and gene therapies.
• Aquark Technologies — Aquark Technologies develops atom systems to develop quantum applications, including atomic clocks, sensors, and navigation systems. Aquark develops a technique to miniaturize cold atom systems using unique laser geometry that is based on more than 10 years of proprietary research at the University of Southampton.
• Productive Machines — Productive Machines Chatter-free Milling Software Optimization Service for every Machine Shop. Apply our recommended spindle speeds and feed rates to your specific machine settings and make the best part, faster, right first time.

Portfolio highlights

• MakeSpace — Save on modern moving & storage. We have customizable solutions for everyone including warehouse storage, self storage, moving, and packing supplies.
• Adentro — Zenreach created Walk-Through Marketing to help businesses with physical locations dramatically improve customer acquisition and lifetime value by connecting digital marketing with in-store results. Zenreach Engage automatically tracks customer visits, effortlessly builds rich customer profiles and keeps them up to date. Zenreach Attract improvesad performance 4x by targeting audiences based on your best customers. Results are measured with our Walk-Through Rate™, a proprietary metric that shows when someone exposed to an ad visits a location. Founded in 2012, Zenreach serves thousands of independent merchants and leading brands like Peet’s Coffee, Ruth’s Chris and BCBG Max Azria.
• DataHub — DataHub Core is the #1 open source platform with a uniquely scalable and extensible metadata graph supporting manual and automated data management. DataHub Cloud is an enterprise-ready SaaS solution providing a fully-managed service of DataHub Core with additional AI-powered capabilities in discovery, observability, and governance to accelerateproduction-readiness of AI and data assets.

Portfolio highlights

• Disc Medicine — Committed to turning scientific discoveries into effective medicines that will disrupt the current standard of care, alleviate suffering, and have a meaningful impact on the lives of patients and their families.
• Accent Therapeutics — Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth anddifferentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, they aim to translate extraordinary science into life-changing therapies for patients.
• Caldera Therapeutics — Caldera Therapeutics is a biotech company developing bispecific antibodies like CLD-423 for IBD and inflammatory diseases. Discover innovative autoimmune treatments today.

Portfolio highlights

• Gamevestor — Be more than a player. Invest in expert-selected video game projects and earn a share of their commercial revenues.
• IsentroniQ — Isentroniq solves the critical cryogenic power and space bottleneck in quantum computing. Our dense, near-heatless wiring solution unlocks 1000x more qubits.
• SWEETECH — SWEETECH is a deeptech startup that specializes in the biosynthesizing of rare sugars (oligosaccharides) using a patented, eco-friendly fermentation platform. Born from a passion for biotechnology and sustainable chemistry.

Portfolio highlights

• Turning Point Therapeutics — The Investor Relations website contains information about Turning Point Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
• Spero Therapeutics — Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterialinfections. Spero’s lead program addresses a novel target driving virulence and persistence of Pseudomonas Aeruginosa infections and other Gram-negative pathogens. The company was founded by Atlas Venture, with financing from SR One and the Partners Innovation Fund.
• Aileron Therapeutics — Aileron Therapeutics - ALRN-6924 - myelopreservation

Portfolio highlights

• Akili Interactive Labs — Akili Interactive is a prescription digital medicine company combining scientific and clinical rigor with the ingenuity of the tech industry to reinvent medicine.
• NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
• Scipio Bioscience — Scipio Bioscience, a Paris-based biotechnology company, provides a novel sample preparation solutionfor single-cell studies, in the form of benchtop kits, for use in sequencing applications in clinical and basic research, in particular transcriptomics.

Portfolio highlights

• Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
• Jounce Therapeutics — Concentra is a biosciences company.
• Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.

Portfolio highlights

• Achaogen — Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrumefficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.
• Standard BioTools — Standard BioTools delivers leading genomic and proteomic solutions. Discover CyTOF, Hyperion and Biomark technologies for deep biological insights.
• Rennovia — Get full access to this domain. Easy, seamless transactions. Zero percent financing available.

Portfolio highlights

• Wyndly — Retrain your allergies through sublingual (under-the-tongue) treatment plans. Virtual appointments. Treatment delivered. Get started after your first consult with a board-certified doctor for $49.99.
• Trial Library — At Trial Library, we partner with the oncology community to enable the discoverability of clinical trials for anyone, anywhere.
• Foresight Diagnostics — We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.

Portfolio highlights

• Elegen — Skip cloning with the only entirely cell-free DNA synthesis provider. Sequences up to 7 kb. Error rates as low as 1:70,000/bp. Manufactured in USA, NGS-verified and shipped globally in as few business days.
• iOrganBio — iOrganBio is a pioneering cell production platform that uses CellForge to facilitate the intelligent manufacturing of human cells and organoids.
• Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.

Portfolio highlights

• Clarifai — Clarifai is the leading Machine Learning, Computer Vision, NLP Platform. Label, train, deploy models on one AI platform for developers & data scientists.
• Primer — Primer makes powerful mission-ready AI software designed to work in your environment, on your data. We help national security teams sift through massive unstructured data sets to find the needle in the haystack, understand and visualize their data, and act collaboratively. Our mission is to empower decisions that can be defended, and acted upon confidently.
• Atavistik Bio — Atavistik Bio is harnessing the power of protein-metabolite interactions to add a new lens to drug discovery.

Portfolio highlights

• Revolut — Join 40+ million customers globally using Revolut to send money to 160+ countries, hold up-to 36 currencies in app, spend in 150+ currencies, and manage their money.
• Platfora — Platfora’s mission is to empower customers to transform their businesses into fact-based enterprises. Platfora's Big Data Analytics Platform masks the complexity of Hadoop, making it easy for customers to understand all the facts in their business across events, actions, behaviors and time.
• Lead — Lead Bank is a community-minded, independent commercial bank with a national client base recognized for its imaginative approach to community banking.

Portfolio highlights

• Brise Pharma — Brise Pharma operates in the scientific research and technical service industry.
• Tuanxiang Pharmaceutical — Tuanxiang Pharmaceutical is an innovative drug research and development company that combines traditional new drug research and development with the use of the world's leading unique phase separation technology.
• Rapafusyn Pharmaceuticals — Rapafuysn is pioneering RapaGlues - a modality of non-degrading molecular glues that addresses hard-to-drug targets.

Portfolio highlights

• Zag Bio — Zag Bio is harnessing the immune system in a whole new way by targeting the thymus to change treatment possibilities for millions of patients with autoimmune diseases.
• PHNX Materials — At PHNX Materials, we transform unusable landfilled coal ash into sustainable products. Join our journey as we leverage cutting-edge chemistry to create a cleaner planet by producing a green SCM, titanium, aluminum and rare-earth elements.
• Faeth Therapeutics — Home | Faeth

Portfolio highlights

• iRiva Medical — iRiva Medical is developing novel neuromodulation therapies to address unmet therapeutic requirements in large patient populations.
• Sensorium Therapeutics — Clinical-stage biotech discovering novel CNS therapies from natural compounds validated by millennia of human use. Anxiety, epilepsy, Alzheimer's.
• TetraLogic Pharmaceuticals — TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. ItsNecrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.

Portfolio highlights

• Umoja Biopharma — Pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells.
• Syndax Pharmaceuticals — Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor,in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.
• Portola Pharmaceuticals — As Alexion, AstraZeneca Rare Disease, we are delivering life-changing therapies to people living with rare diseases.

Portfolio highlights

• Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
• Degron Therapeutics — Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment.
• Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.

Portfolio highlights

• Scopely — Scopely is a global interactive entertainment and mobile-first games company, home to many top-grossing, award-winning franchises including “Star Trek™ Fleet Command,” “MARVEL Strike Force,” “Scrabble® GO,” “WWE Champions” and “Yahtzee® With Buddies,” among others. Scopely creates, publishes and live-operates immersive games that empower adirected-by-consumer™ experience. Founded in 2011, Scopely is fueled by a world-class team and a proprietary technology platform Playgami that supports one of the most diversified portfolios in the mobile games industry. Recognized multiple times as one of Fast Company’s “World’s Most Innovative Companies,” Scopely is a multi-billion-dollar business due to its ability to create long-lasting game experiences that players enjoy for years. Scopely has global operations across 17 markets (Asia-Pacific - Bangalore, Seoul, Shanghai, Singapore, Tokyo; EMEA - Barcelona, Dublin, Helsinki, Kyiv, London, Seville, Tel Aviv; North America - Boston, Boulder, Culver City, Mountain View, San Francisco), with additional game studio partners across four continents. For more information, visit www.scopely.com.
• Fano Labs — We are one of the leading AI companies specialising on Language AI technologies for enterprises in customer services, compliance and other lines of businesses.
• Amper Music — Amper is an AI music composition company that develops tools for content creators of all kinds. Learn about our new enterprise platform, Score, as well as our creator API.

Portfolio highlights

• Laigo Bio — Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders.
• Adcytherix — Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.
• DAMAE Medical — Damae Medical is a Paris, France-based medtech company. It has developed a medical device capable of seeing biological tissues in depth, at a cellular level and in vivo. This innovative optical imaging technology will especially allow dermatologists to evaluate in a precise, efficient and rapid way malignancy of tumors by a simple contact with thesurface of the skin. DAMAE Medical’s mission is to put the great power of bio-photonics at the service of opening new opportunities in medical imaging and diagnosis.

Portfolio highlights

• IFM Therapeutics — IFM Therapeutics is a provider of small molecule that module novel targets in the innate immune system. The company and its academic collaborators combine unparalleled expertise in innate immunity with seasoned drug discovery and development professionals. Its subsidiary IFM Due is focused on the discovery and developing antagonists of thecGAS/STING pathway for the treatment of inflammation, neuroinflammation, autoimmunity and cancer. IFM Discovery, a newly financed incubator entity within the IFM enterprise, is prosecuting a basket of genetically-validated targets as next-generation therapies for inflammation, neuroinflammation, autoimmunity and fibrosis
• NRG Therapeutics — energizing drug discovery in neurodegenerative diseases.
• Scorpion Therapeutics — We are developing drugs specifically designed to interact with validated cancer targets with greater selectivity and optimized pharmaceutical properties to improve their safety and efficacy.

Portfolio highlights

• Quid — Empower your business with Quid's Generative AI platform to gain a holistic view of customer context. See data through the lens of the future. AI-powered consumer and market intelligence.
• Activ Surgical — Activ Surgical provides Intraoperative Surgical Intelligence aimed at transforming healthcare standards and reducing complication rates.
• Second Front Systems — The continuous accreditation and deployment of commercial software is crucial for U.S. national security missions. With Second Front Systems' Game Warden platform, you'll be achieving exactly that.

Portfolio highlights

• NOVAMEAT — NOVAMEAT produces plant-based meat substitutes through advanced food printing and tissue engineering technologies. Join the #novameat movement.
• CellCentric — CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
• Braveheart Bio — Advancing treatments to improve outcomes and quality of life for patients with hypertrophic cardiomyopathy and related heart conditions.

Portfolio highlights

• NRG Therapeutics — energizing drug discovery in neurodegenerative diseases.
• Nitrase Therapeutics — Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is onParkinson's disease, the company aims to expand its proprietary platform to include other disease indications.
• Violet Therapeutics — Violet Therapeutics is a healthcare company that operates in stealth mode.

Portfolio highlights

• DiogenX — Welcome to DiogenX. Explore our pioneering research and innovative therapies aimed at transforming diabetes treatment
• Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
• MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

Portfolio highlights

• Liberate Bio — Liberate Bio focuses on advancing non-viral delivery technologies for nucleic acid cargoes such as ASOs and siRNAs. The company aims to develop new vehicles to deliver oligonucleotide cargos, addressing genetic disorders. With a team of 50 employees, Liberate Bio operates within the biotechnology industry, working on innovative solutions fortargeted delivery systems.
• Li Industries — At Li Industries, we are building battery recycling technologies that enable greater automation, competitiveness, and sustainability.
• LanzaTech — LanzaTech is turning our global carbon crisis into a feedstock opportunity with the potential to displace 30% of crude oil use today and reduce global CO2 emissions by 10%. By recycling carbon from industrial off-gases; syngas generated from any biomass resource (e.g. municipal solid waste (MSW), organic industrial waste, agricultural waste); andreformed biogas, LanzaTech can reduce emissions and make new products for a circular carbon economy.LanzaTech’s carbon recycling technology is like retrofitting a brewery onto an emission source like a steel mill or a landfill site, but instead of using sugars and yeast to make beer, pollution is converted by bacteria to fuels and chemicals! Imagine a day when your plane is powered by recycled GHG emissions, when your yoga pants started life as pollution from a steel mill. This future is possible using LanzaTech technology.

Portfolio highlights

• Ensoma — Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.
• OSPRI — Multiplex qPCR reagent kits for assay development, biomarker discovery, and translational research. 120+ configurations across a broad range of research areas. Extraction-free. Customizable. For Research Use Only.
• Leo Cancer Care — Leo Cancer Care is the more human way to treat cancer, built on research from across the globe showing the benefits of upright patient positioning. Combined with a shift from machine rotation to patient rotation, Leo Cancer Care is set to change the face of Radiation Therapy for good. Finding a bett

Portfolio highlights

• Precirix — Developing radio-immunotherapeutic drugs for cancer patients.
• IVERIC bio — IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inheritedretinal diseases.
• Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.

Portfolio highlights

• Lila Sciences — Lila Sciences is a platform that uses artificial intelligence to support research in life sciences, chemical sciences, and materials sciences. It develops AI-driven tools and autonomous labs to improve research efficiency and facilitate scientific discoveries. The platform is designed to enhance various aspects of the scientific method andcontribute to advancements in technology and innovation.
• Montai Therapeutics — Harnessing untapped diverse chemistry with AI-enabled drug discovery to develop breakthrough small molecule medicines for chronic disease.
• Expedition Medicines — Defining a new era in drug discovery where chemistry rewrites the rules of biology to engage any protein target.

Portfolio highlights

• Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
• Synthesize Bio — Deep biomedical data is the key to unlocking discoveries and creating therapies. Synthesize Bio uses AI to reduce data collection and analysis from months to minutes for a fraction of the cost in time, personnel, and materials.
• Archon Biosciences — Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management.

Portfolio highlights

• Immutrin — Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils.
• Truthsystems — Truth Systems offers real-time compliance agents that prevent human error by embedding behavioral guardrails into AI interactions.
• Bluebird Kids Health — Bluebird Kids Health is launching a proprietary technology platform to proactively manage and coordinate treatment, with AI enhancing and simplifying the experience for its clinical team.

Portfolio highlights

• FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
• Hepster — hepster, die Onlineversicherung, flexibel, sicher und immer 100% digital.
• BAOUW / Outdoor Organic Nutrition — A raw, healthy, and natural diet made up of energy gels, energy bars, and energy fruit purees.

Portfolio highlights

• Apella Technology — Apella is an AI startup that brings modern engineering to improve surgery. It collects data from operating rooms in hospitals via sensors and puts artificial intelligence to the task of analyzing that information and spits it out in a way that that the startup says can be interpreted by hospitals to improve operations, surgical quality, training,and even real-time decision-making.Apella was founded in 2019 and is headquartered in San Francisco, California.
• Beacon Biosignals — AI + EEG to change the way patients are treated for disorders of the brain.
• Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.

Portfolio highlights

• LOLIWARE — LOLIWARE is rewriting the story of destructive packaging. By harnessing the power of seaweed to replace plastic at scale, LOLIWARE is tapping into its potential to regenerate our ocean and decarbonize our planet.
• Kolors — Kolors is a technological platform that focuses on providing intelligent intercity mobility of bus transportation in the region.
• ARRIS — Using next-gen advanced manufacturing technologies, ARRIS Composites produces smarter, lighter, stronger, and more sustainable products at scale.

Portfolio highlights

• Ensoma — Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.
• Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
• BlossomHill Therapeutics — BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.

Portfolio highlights

• Ensoma — Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.
• Mendra — Mendra is a biopharmaceutical company that uses AI to accelerate clinical development and commercialization of breakthrough medicines for diseases with high unmet need.
• Kinaset Therapeutics — Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts.

Portfolio highlights

• Moximed — Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis.
• Gossamer Bio — Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focuson areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
• Sagimet Biosciences — Sagimet Biosciences better reflects our expertise in fatty acid metabolism and current focus on developing ground-breaking therapeutics to treat the liver disease NASH.

Portfolio highlights

• FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
• Neu Health — Neu Health enables clinicians, care givers and patients to tackle this growing challenge with cutting-edge digital technologies designed to make the latest care accessible for all, improving outcomes today and accelerating future breakthroughs.
• Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.